Redeye is impressed with Arise’s sale of Kölvallen, with an expected EBITDA contribution of about EU...
Q2 due Thursday 21 July, 08:30 CET We expect strong orders and sales but weak EBIT 35x-13x ‘22e-‘23e...
Redeye endorses ISAB’s new IRS order from a US client worth SEK 1.
Bra fart i den underliggande försäljningen Bolaget visade en nettoomsättning under Q1'22 på 3,4 mkr ...
Fortsatt stark organiskt tillväxt... Över lag rapporterade Midway ett mycket imponerande resultat oc...
Redeye updates its valuation of Cantargia after the terms of its rights issue have been announced.
Q2 Sales 3% above but EBIT 66% below Components the issue in Q2, price hikes implemented Cons ‘22e ...
Strong top line, 3% above ABGSC Underlying profitability weak, set to improve from now CEO announc...
Redeye comments in Invisio ahead of its Q2-results (due 22 July) where we expect performance to rema...
Redeye thinks the Q2 report was weak and indicated a hesitant market climate.
Redeye states that the Q2 report was soft in terms of sales, but that profitability held up well des...
Effective operational delivery Improved debt metrics post value gains & acquisition 12.
EBITDA 8% above cons, discontinuing non-core areas Initial signs of lower IVF cycle growth near-ter...
Q2 beat on sales, below on EBITA We expect the project market to slow, starting in H1’23 We lower ’2...
Sales -24% y-o-y, 8% below our expectations Strong GM held up EBIT, but some temporary effects We ...
Fram divests its IT Development business and refines its business model further.
Bolaget har pågående projekt i flertalet områden som kan innebära stor potential och senaste tidens ...
Positiv tillväxt trots svaghet i online Försäljningen i Q2 växte med 2,1%, där tillväxten i butik vä...
Redeye embraces yet another record quarter from BONESUPPORT, continuing to support our thesis and fi...
Redeye comments on Episurf’s Q2 report and notes a quarter in line with our expectations both financ...
